Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe

Ene Ly Jõgeda, Radko Avi, Merit Pauskar, Eveli Kallas, Tõnis Karki, Don Des Jarlais, Anneli Uusküla, Irja Lutsar, Kristi Huik

Research output: Contribution to journalArticle

Abstract

Background: In Europe, human T-lymphotropic virus (HTLV) type 2 mainly occurs among intravenous drug users (IDUs) with prevalence up to 15% and HTLV-1 among general population with prevalence <. 1%. However, there is no data regarding the prevalence of HTLV-1 or HTLV-2 in Eastern European IDUs population where HIV prevalence is relatively high. We aimed to determine the prevalence and genotypes of HTLV-1/HTLV-2 among IDUs and healthy volunteers in Estonia. Methods: The study included 345 IDUs and 138 healthy volunteers. The presence of HTLV-1/HTLV-2 was determined by nested PCR; positive and negative controls were used in every PCR run. Results: The analysed IDUs resembled the IDUs of HIV epidemic in Estonia: mainly male (79%) with median age of 30 years (interquartile range [IQR] 25-34), and prolonged duration of intravenous drug usage (11 years; IQR 7-14). The prevalence exposure to blood-borne viral infections was high - 50% were HIV positive, 88% hepatitis C positive, 67% hepatitis B positive. Of IDUs, 64% reported receptive needle sharing in the past and 18% at least once a month during last six months. None of the IDUs carried HTLV-1 but there was a case of HTLV-2 (prevalence 0.3%; 95% CI 0.1-1.6). All healthy volunteers were HTLV-1 and HTLV-2 PCR negative. Conclusion: This is the first study investigating the prevalence of HTLV-1/HTLV-2 among high risk population and healthy volunteers in Eastern European region. Our results suggest that despite other widely spread blood-borne infections (e.g. HIV, HBV, HCV) HTLV-1 and HTLV-2 are rare among IDUs in Estonia.

Original languageEnglish (US)
Pages (from-to)83-85
Number of pages3
JournalInfection, Genetics and Evolution
Volume43
DOIs
StatePublished - Sep 1 2016

Fingerprint

drug user
Human T-lymphotropic virus 2
Primate T-lymphotropic virus 2
Primate T-lymphotropic virus 1
Eastern Europe
Human T-lymphotropic virus 1
Eastern European region
Drug Users
virus
drugs
viruses
Estonia
Healthy Volunteers
volunteers
human immunodeficiency virus
HIV
Polymerase Chain Reaction
Needle Sharing
Population
hepatitis

Keywords

  • Blood-borne infection
  • Co-infection
  • HIV
  • HTLV-1/2

ASJC Scopus subject areas

  • Microbiology
  • Ecology, Evolution, Behavior and Systematics
  • Molecular Biology
  • Genetics
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. / Jõgeda, Ene Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi.

In: Infection, Genetics and Evolution, Vol. 43, 01.09.2016, p. 83-85.

Research output: Contribution to journalArticle

Jõgeda, Ene Ly ; Avi, Radko ; Pauskar, Merit ; Kallas, Eveli ; Karki, Tõnis ; Des Jarlais, Don ; Uusküla, Anneli ; Lutsar, Irja ; Huik, Kristi. / Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. In: Infection, Genetics and Evolution. 2016 ; Vol. 43. pp. 83-85.
@article{33a53167be11481ea0c3336ba3e5ec76,
title = "Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe",
abstract = "Background: In Europe, human T-lymphotropic virus (HTLV) type 2 mainly occurs among intravenous drug users (IDUs) with prevalence up to 15{\%} and HTLV-1 among general population with prevalence <. 1{\%}. However, there is no data regarding the prevalence of HTLV-1 or HTLV-2 in Eastern European IDUs population where HIV prevalence is relatively high. We aimed to determine the prevalence and genotypes of HTLV-1/HTLV-2 among IDUs and healthy volunteers in Estonia. Methods: The study included 345 IDUs and 138 healthy volunteers. The presence of HTLV-1/HTLV-2 was determined by nested PCR; positive and negative controls were used in every PCR run. Results: The analysed IDUs resembled the IDUs of HIV epidemic in Estonia: mainly male (79{\%}) with median age of 30 years (interquartile range [IQR] 25-34), and prolonged duration of intravenous drug usage (11 years; IQR 7-14). The prevalence exposure to blood-borne viral infections was high - 50{\%} were HIV positive, 88{\%} hepatitis C positive, 67{\%} hepatitis B positive. Of IDUs, 64{\%} reported receptive needle sharing in the past and 18{\%} at least once a month during last six months. None of the IDUs carried HTLV-1 but there was a case of HTLV-2 (prevalence 0.3{\%}; 95{\%} CI 0.1-1.6). All healthy volunteers were HTLV-1 and HTLV-2 PCR negative. Conclusion: This is the first study investigating the prevalence of HTLV-1/HTLV-2 among high risk population and healthy volunteers in Eastern European region. Our results suggest that despite other widely spread blood-borne infections (e.g. HIV, HBV, HCV) HTLV-1 and HTLV-2 are rare among IDUs in Estonia.",
keywords = "Blood-borne infection, Co-infection, HIV, HTLV-1/2",
author = "J{\~o}geda, {Ene Ly} and Radko Avi and Merit Pauskar and Eveli Kallas and T{\~o}nis Karki and {Des Jarlais}, Don and Anneli Uusk{\"u}la and Irja Lutsar and Kristi Huik",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.meegid.2016.05.022",
language = "English (US)",
volume = "43",
pages = "83--85",
journal = "Infection, Genetics and Evolution",
issn = "1567-1348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe

AU - Jõgeda, Ene Ly

AU - Avi, Radko

AU - Pauskar, Merit

AU - Kallas, Eveli

AU - Karki, Tõnis

AU - Des Jarlais, Don

AU - Uusküla, Anneli

AU - Lutsar, Irja

AU - Huik, Kristi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: In Europe, human T-lymphotropic virus (HTLV) type 2 mainly occurs among intravenous drug users (IDUs) with prevalence up to 15% and HTLV-1 among general population with prevalence <. 1%. However, there is no data regarding the prevalence of HTLV-1 or HTLV-2 in Eastern European IDUs population where HIV prevalence is relatively high. We aimed to determine the prevalence and genotypes of HTLV-1/HTLV-2 among IDUs and healthy volunteers in Estonia. Methods: The study included 345 IDUs and 138 healthy volunteers. The presence of HTLV-1/HTLV-2 was determined by nested PCR; positive and negative controls were used in every PCR run. Results: The analysed IDUs resembled the IDUs of HIV epidemic in Estonia: mainly male (79%) with median age of 30 years (interquartile range [IQR] 25-34), and prolonged duration of intravenous drug usage (11 years; IQR 7-14). The prevalence exposure to blood-borne viral infections was high - 50% were HIV positive, 88% hepatitis C positive, 67% hepatitis B positive. Of IDUs, 64% reported receptive needle sharing in the past and 18% at least once a month during last six months. None of the IDUs carried HTLV-1 but there was a case of HTLV-2 (prevalence 0.3%; 95% CI 0.1-1.6). All healthy volunteers were HTLV-1 and HTLV-2 PCR negative. Conclusion: This is the first study investigating the prevalence of HTLV-1/HTLV-2 among high risk population and healthy volunteers in Eastern European region. Our results suggest that despite other widely spread blood-borne infections (e.g. HIV, HBV, HCV) HTLV-1 and HTLV-2 are rare among IDUs in Estonia.

AB - Background: In Europe, human T-lymphotropic virus (HTLV) type 2 mainly occurs among intravenous drug users (IDUs) with prevalence up to 15% and HTLV-1 among general population with prevalence <. 1%. However, there is no data regarding the prevalence of HTLV-1 or HTLV-2 in Eastern European IDUs population where HIV prevalence is relatively high. We aimed to determine the prevalence and genotypes of HTLV-1/HTLV-2 among IDUs and healthy volunteers in Estonia. Methods: The study included 345 IDUs and 138 healthy volunteers. The presence of HTLV-1/HTLV-2 was determined by nested PCR; positive and negative controls were used in every PCR run. Results: The analysed IDUs resembled the IDUs of HIV epidemic in Estonia: mainly male (79%) with median age of 30 years (interquartile range [IQR] 25-34), and prolonged duration of intravenous drug usage (11 years; IQR 7-14). The prevalence exposure to blood-borne viral infections was high - 50% were HIV positive, 88% hepatitis C positive, 67% hepatitis B positive. Of IDUs, 64% reported receptive needle sharing in the past and 18% at least once a month during last six months. None of the IDUs carried HTLV-1 but there was a case of HTLV-2 (prevalence 0.3%; 95% CI 0.1-1.6). All healthy volunteers were HTLV-1 and HTLV-2 PCR negative. Conclusion: This is the first study investigating the prevalence of HTLV-1/HTLV-2 among high risk population and healthy volunteers in Eastern European region. Our results suggest that despite other widely spread blood-borne infections (e.g. HIV, HBV, HCV) HTLV-1 and HTLV-2 are rare among IDUs in Estonia.

KW - Blood-borne infection

KW - Co-infection

KW - HIV

KW - HTLV-1/2

UR - http://www.scopus.com/inward/record.url?scp=84969792622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969792622&partnerID=8YFLogxK

U2 - 10.1016/j.meegid.2016.05.022

DO - 10.1016/j.meegid.2016.05.022

M3 - Article

C2 - 27223634

AN - SCOPUS:84969792622

VL - 43

SP - 83

EP - 85

JO - Infection, Genetics and Evolution

JF - Infection, Genetics and Evolution

SN - 1567-1348

ER -